Nicholas Yozamp, MD
Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1275914475
Payments from drug & device makers
Across 194 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$484
- Abbott$273
- Amgen$194
- Medtronic$176
- Dexcom, Inc.$164
- plus $612 from 13 others
What the payments were for
- Food & beverage$3,660100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 101 | $1,757 |
| Lilly USA, LLC | 27 | $484 |
| Abbott | 13 | $273 |
| Amgen | 9 | $194 |
| Medtronic | 5 | $176 |
| Dexcom, Inc. | 9 | $164 |
| Novo Nordisk | 7 | $150 |
| Novartis | 4 | $92 |
| Sanofi-aventis U.S. LLC | 4 | $90 |
| Boehringer Ingelheim | 3 | $47 |
| Exact Sciences | 2 | $46 |
| Radius Health, Inc. | 2 | $41 |
| BETA Bionics, Inc. | 2 | $36 |
| Recor Medical Inc | 1 | $31 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Pfizer | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$108
How this compares
$3,660 in reported general payments places this provider in the 55th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 353 | $558,716 |
| OzempicSemaglutide | 312 | $522,203 |
| FarxigaDapagliflozin Propanediol | 351 | $373,516 |
| EliquisApixaban | 255 | $241,316 |
| TrulicityDulaglutide | 142 | $227,700 |
| JardianceEmpagliflozin | 166 | $190,482 |
| JanuviaSitagliptin Phosphate | 79 | $79,152 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 29 | $76,178 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $73,578 |
| Dupixent PenDupilumab | 14 | $53,517 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 75 | $35,977 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $35,628 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 226 | $34,835 |
| Humalog Kwikpen U-100Insulin Lispro | 74 | $31,675 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 63 | $30,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $484 | $803,286566 claims |
| Novo NordiskOzempic, Fiasp, Novolog, Rybelsus | $150 | $570,127399 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,757 | $384,708368 claims |
| PfizerEliquis | $15 | $241,316255 claims |
| Boehringer IngelheimJardiance, Tradjenta | $47 | $209,972194 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $90 | $25,03814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Louis
- Thomas NickolasSaint Louis$945K
- Anne GoldbergSaint Louis$830K
- Janet McGillSaint Louis$828K
- Julie SilversteinSaint Louis$536K
- Sandeep DhindsaSaint Louis$173K
- Maamoun SalamSaint Louis$170K
- Michael WhyteSaint Louis$133K
- Fumihiko UranoSaint Louis$122K
- Farid RomanSaint Louis$62K
- Kathryn DiemerSaint Louis$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.